Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 1.00 |
| ▸ | CES1 | P23141 | 2/20 | 1.00 |
| ▸ | DAO | P14920 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 7/20 | 0.62 |
| ▸ | NPC1 | O15118 | 6/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 3/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HPGDS | O60760 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9148741 | 0.90 | CES2 (0.81) | CES2CES1DAORAB9ANPC1 | |
| SCHEMBL71555 | 0.87 | CES2 (0.77) | CES2CES1DAORAB9ANPC1 | |
| SCHEMBL14947051 | 0.87 | CES2 (0.75) | CES2CES1DAORAB9ANPC1 | |
| Ammonia Solution, Strong SCHEMBL11721426 | 0.85 | CES2 (0.74) | CES2CES1DAORAB9ANPC1 | |
| SCHEMBL1883541 | 0.85 | CES2 (0.74) | CES2CES1DAORAB9ANPC1 | |
| SCHEMBL4765889 | 0.85 | CES2 (0.74) | CES2CES1DAORAB9ANPC1 | |
| SCHEMBL2610951 | 0.85 | CES2 (0.74) | CES2CES1DAORAB9ANPC1 | |
| Water SCHEMBL27559900 | 0.85 | CES2 (0.74) | CES2CES1DAORAB9ANPC1 | |
| SCHEMBL8310773 | 0.85 | CES2 (0.72) | CES2CES1DAORAB9ANPC1 | |
| SCHEMBL11601470 | 0.84 | CES2 (0.71) | CES2CES1DAORAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025087819-A1 | CATALYST AND METHOD FOR PRODUCING HYDROGEN BY PROTON REDUCTION | RENER (FR) | 2025-05-01 | — | — | WO | claimed |
| CN-116023294-A | Preparation method and application of oxygen absorbing material ligand | 威格科技(苏州)股份有限公司 | 2023-04-28 | — | — | CN | claimed |
| US-9206196-B1 | Derivatives of benzoxazino quinoline, benzoxazino isoquinoline and processes for their preparation | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (US) | 2015-12-08 | — | — | US | claimed |
| US-7973034-B2 | Ameliorating toxic effects of such as cancer therapy drugs or addictive drug overdose | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2011-07-05 | — | — | US | claimed |
| WO-2025087819-A1 | CATALYST AND METHOD FOR PRODUCING HYDROGEN BY PROTON REDUCTION | RENER (FR) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025087819-A1 | CATALYST AND METHOD FOR PRODUCING HYDROGEN BY PROTON REDUCTION | RENER (FR) | 2025-05-01 | — | — | WO | disclosed |
| US-12195450-B2 | Small molecule neutral sphingomyelinase 2 (nSMase2) inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| WO-2023220463-A1 | METHODS OF FORMING AN OBJECT IN A VOLUME OF A PHOTOHARDENABLE COMPOSITION | QUADRATIC 3D, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| CN-115869923-A | Oxygen absorbing material, preparation method thereof and prepared adsorbing material capable of adsorbing oxygen and organic solvent simultaneously | 威格科技(苏州)股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| WO-2022156793-A1 | QUINOXALINE-BASED D-A-D NEAR-INFRARED TWO-REGION FLUORESCENT MOLECULE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2022-07-28 | — | — | WO | disclosed |
| US-20220119374-A1 | SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (nSMase2) INHIBITORS | THE JOHNS HOPKINS UNIVERSITY | 2022-04-21 | — | — | US | disclosed |
| US-20220117958-A1 | COMPOSITIONS AND METHODS FOR INHIBITING ACSS2 | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2022-04-21 | — | — | US | disclosed |
| US-20050203155-A1 | Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections | AXXIMA PHARMACEUTICAL AG. (DE) | 2005-09-15 | — | — | US | disclosed |
| EP-1532118-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2005-05-25 | — | — | EP | disclosed |
| WO-2005030705-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
| US-20050054691-A1 | Carboxylesterase inhibitors | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2005-03-10 | — | — | US | disclosed |
| WO-2005007099-A2 | PKB INHIBITORS AS ANTI-TUMOR AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2005-01-27 | — | — | WO | disclosed |
| WO-2004096800-A2 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | NOVARTIS AG (CH) | 2004-11-11 | — | — | WO | disclosed |
| US-6713781-B1 | Organic light-emitting device having phenanthroline-fused phenazine | CANON KABUSHIKI KAISHA (JP) | 2004-03-30 | — | — | US | disclosed |
| WO-2004005264-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | AXXIMA PHARMACEUTICALS AG (DE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054691-A1 | Carboxylesterase inhibitors | CES1, CES2, BCHE | CES2 2/4885CES1 1/4885DAO 302/4885 |
| US-12195450-B2 | Small molecule neutral sphingomyelinase 2 (nSMase2) inhibitors | SMPD2, SPTLC2, SGMS2 | CES2 246/4885CES1 191/4885DAO 3200/4885 |
| US-20050203155-A1 | Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections | CSNK1G1, CSNK1E, CSNK1D | CES2 1576/4885CES1 188/4885DAO 1282/4885 |
| US-20220119374-A1 | SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (nSMase2) INHIBITORS | SMPD2, SPTLC2, SGMS2 | CES2 246/4885CES1 191/4885DAO 3200/4885 |
| US-20220117958-A1 | COMPOSITIONS AND METHODS FOR INHIBITING ACSS2 | ACSS2, ACSL3, ACSL1 | CES2 595/4885CES1 159/4885DAO 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.